4592 — SanBio Co Share Price
0.000.00%
Last trade - 00:00- ¥164bn
- ¥162bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 93.06 | ||
| Price to Tang. Book | 95.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -129.15% | ||
| Return on Equity | -126.57% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jan | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | n/a | n/a | n/a | n/a | n/a | 1,530 | 2,115 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
Directors
- Toru Kawanishi CHM (51)
- Keita Mori PRE (54)
- Akihiro Tsujimura VPR (53)
- Yoshihiro Sumiya EXO
- Chris Horan EXO
- Bijan Nejadnik EXO
- Naoki Tsukahara EXO
- Hiroshi Yamamoto EXO (40)
- Noboru Kotani IND (64)
- Last Annual
- January 31st, 2025
- Last Interim
- January 31st, 2025
- Incorporated
- February 27th, 2013
- Public Since
- April 8th, 2015
- No. of Employees
- 29
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 72,014,824
- Address
- 13F, St. Luke Tower, 8-1, Akashi-cho, CHUO-KU, 104-0044
- Web
- https://www.sanbio.com/
- Phone
- +81 362643481
- Auditors
- Deloitte Touche Tohmatsu LLC
Upcoming Events for 4592
Q1 2026 SanBio Co Ltd Earnings Release
Dividend For 4592.T - 0.0000 JPY
Q2 2026 SanBio Co Ltd Earnings Release
Similar to 4592
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the SanBio Co share price?
As of Today at 23:02 UTC, shares in SanBio Co are trading at ¥2,278. This share price information is delayed by 15 minutes.
How has the SanBio Co share price performed this year?
Shares in SanBio Co last closed at ¥2,278 and the price had moved by +438.53% over the past 365 days. In terms of relative price strength the SanBio Co share price has outperformed the Nikkei 225 Index by +488.16% over the past year.
What are the analyst and broker recommendations for SanBio Co?
The overall consensus recommendation for SanBio Co is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the SanBio Co dividend yield?
SanBio Co does not currently pay a dividend.
Does SanBio Co pay a dividend?
SanBio Co does not currently pay a dividend.
When does SanBio Co next pay dividends?
SanBio Co does not currently pay a dividend.
How do I buy SanBio Co shares?
To buy shares in SanBio Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of SanBio Co?
As of the previous close price of ¥2,278, shares in SanBio Co had a market capitalisation of ¥164bn.
Where are SanBio Co shares listed?
Here are the trading details for SanBio Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4592
What kind of share is SanBio Co?
Based on an overall assessment of its quality, value and momentum SanBio Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a SanBio Co share price forecast for 2025?
The analyst consensus target price for shares in SanBio Co is ¥1,320. That is 42.05% below the last closing price of ¥2,278.
Analysts covering SanBio Co currently have a consensus Earnings Per Share (EPS) forecast of -¥52 for the next financial year.
Find out moreWhat is the trend in the SanBio Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SanBio Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +147.04%.
As of the last closing price of ¥2,278, shares in SanBio Co were trading +111.48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the SanBio Co PE Ratio?
The SanBio Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥2,278.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of SanBio Co?
SanBio Co's management team is headed by:
- Toru Kawanishi - CHM
- Keita Mori - PRE
- Akihiro Tsujimura - VPR
- Yoshihiro Sumiya - EXO
- Chris Horan - EXO
- Bijan Nejadnik - EXO
- Naoki Tsukahara - EXO
- Hiroshi Yamamoto - EXO
- Noboru Kotani - IND